These found have led to the development approval of three BRAF inhibitors as well as five combinations of a BRAF inhibitor to manage cancer such as anaplastic thyroid cancer, melanoma, non-small cell lung cancer and colorectal cancer [18]. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.